{"nctId":"NCT00975221","briefTitle":"Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy","startDateStruct":{"date":"2010-03-10","type":"ACTUAL"},"conditions":["Hyperparathyroidism, Primary","Hypercalcemia"],"count":67,"armGroups":[{"label":"Cinacalcet","type":"EXPERIMENTAL","interventionNames":["Drug: Cinacalcet"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Cinacalcet","Drug: Placebo"]}],"interventions":[{"name":"Cinacalcet","otherNames":["Sensipar","Mimpara"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of primary hyperparathyroidism (HPT)\n* subjects must have the following laboratory values:\n\n  1. local/historical laboratory result showing a corrected total serum calcium \\> 1 mg/dL (0.25 mmol/L) above the upper limit of normal and\n\n     ≤ 12.5 mg/dL (3.12 mmol/L) within the past 12 months, and\n     * local/historical laboratory result showing a plasma parathyroid horone (PTH) \\> 75% of upper limit of normal within the past 12 months, and\n     * one central laboratory draw at the screen visit showing a corrected total serum calcium \\> 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL (3.12 mmol/L), and\n     * one central laboratory draw at the screen visit showing a plasma PTH \\> 55 pg/mL (5.8 pmol/L) OR\n  2. two central laboratory draws performed during the screening period at least 7 days apart, showing a\n\n     * corrected total serum calcium \\> 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL (3.12 mmol/L), and\n     * plasma PTH \\> 55 pg/mL (5.8 pmol/L)\n* not able to undergo parathyroidectomy for ≥ 1 of the following reasons:\n\n  * failed parathyroidectomy\n  * comorbid conditions contraindicating parathyroidectomy\n  * parathyroidectomy not considered appropriate or is not feasible by primary physician and subject\n* before any study-specific procedure is performed, the appropriate written informed consent must be obtained\n\nExclusion Criteria:\n\n* symptoms attributable to hypercalcemia, requiring immediate medical intervention, as judged by the investigator (including acute kidney stone, nausea and vomiting requiring intravenous hydration, confusion, lethargy, stupor, or coma)\n* unstable medical condition, defined as having been hospitalized within 30 days before the date of informed consent, or otherwise unstable in the judgment of the investigator\n* administration of drugs that increase serum calcium concentration, including but not limited to thiazide diuretics or lithium\n* initiated bisphosphonate therapy or changed bisphosphonate dose within 12 weeks before the date of informed consent\n* current administration of drugs for ventricular arrhythmia\n* unable to provide informed consent, or is at risk for poor compliance with study procedures\n* currently enrolled in another investigational device or drug study(s), or completed such study within 30 days before the date of informed consent\n* known hypersensitivity to or unable to tolerate cinacalcet\n* received treatment with cinacalcet within 60 days before the date of informed consent\n* history of seizures or an adjustment of anti-seizure medication within 12 weeks before the date of informed consent\n* family history or diagnosis a genetic syndrome, such as familial benign hypocalciuric hypercalcemia (FBHH) or multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2), where primary HPT is one of the clinical manifestations of familial benign hypocalciuric hypercalcemia (FBHH)\n* refused to use highly effective contraceptive measures (as determined by the investigator) throughout the study\n* pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"75.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥ 1 mg/dL (0.25 mmol/L) Decrease From Baseline in Mean Corrected Total Serum Calcium Concentration During the EAP","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"84.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Corrected Total Serum Calcium Concentration During the EAP","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.66","spread":"0.99"},{"groupId":"OG001","value":"-15.21","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Plasma Parathyroid Hormone Level During the EAP","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"4.05"},{"groupId":"OG001","value":"-23.80","spread":"4.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":34},"commonTop":["Nausea","Muscle spasms","Diarrhoea","Headache","Abdominal pain upper"]}}}